



## EOS imaging Announces Installations at Two Leading German Hospitals

*Heidelberg University Orthopedic Hospital and the Medical Center of the University of Munich  
select EOS for 2D/3D imaging and treatment planning*

Paris, June 23, 2015 – EOS imaging (Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopedic medical imaging and associated solutions, today announced dual EOS imaging system installations at two of the leading, and largest, academic hospitals in Germany – Heidelberg University Orthopedic Hospital and the Medical Center of the University of Munich.

Heidelberg Orthopedic Hospital records more than 6,000 inpatient and more than 50,000 outpatient treatments each year ranging from orthopedic pathologies to injuries of the musculoskeletal system. In line with the hospital's motto, "Life is Movement", Heidelberg Orthopedic Hospital medical team is dedicated to the restoration and improvement of patient's mobility using conservative orthopedics and high precision surgery.

The University Hospital of Munich has 2,200 beds and 45 clinics, Institutes and Departments including a dedicated joint replacement center that further to performing high volumes of surgeries also specializes in revision arthroplasties. With its two campuses in Grosshadern and in the city center, the University Hospital of Munich is one of the largest hospitals in Europe.

"We maintain our position as one of Germany's largest, and we would argue best, orthopedics hospital by ensuring that our physicians and surgeons have access to the best tools and treatments for our patients. EOS will serve important research projects of our hospital as well as provide cutting edge imaging support for the treatment of complex spinal conditions in children and adults while reducing radiation exposure to an extremely low level," said Dr. Christof Birkenmaier, Orthopedic Surgeon at University Hospital of Munich.

"We see a number of immediate opportunities to improve our current quality of care using EOS, specifically, by improving surgical planning and safely monitoring the success of bracing treatments. We also look forward to partnering with EOS imaging to determine the utility of EOS images for a broad range of additional uses," added Dr. Volker Ewerbeck, Director of Orthopedics and Traumatology at Heidelberg University Orthopedic Hospital.

Marie Meynadier, CEO of EOS imaging, said, "These key installations further illustrate the growing adoption rate of EOS with recognition by the highest-regarded orthopedics departments in Germany. We are proud to provide EOS imaging services to the Heidelberg Orthopedics Hospital and the Medical Center of the University of Munich and we look forward to helping these two prestigious sites provide even better services to their patients."

The EOS® system provides full-body stereo-radiographic images of patients in functional positions, in both 2D and 3D. EOS exams require a radiation dose 50% to 85% less than Digital Radiology and 95% less than basic CT scans, as well as related software solutions. The new EOS Micro Dose option, recently cleared by the Food and Drug Administration, allows a further drastic step towards the ALARA principle (As Low As Reasonably Achievable) by bringing pediatric spine follow up exams at a dose level equivalent to a week of natural background radiation on Earth.

For further information about the Company or EOS®, the first full body, low dose 2D/3D imaging system, please visit <http://www.eos-imaging.com/>.



**EOS imaging has been chosen to be included in the new EnterNext© PEA-PME 150 index, composed of 150 French companies and listed on Euronext and Alternext markets in Paris.**



EOS imaging is listed on Compartment C of Euronext Paris  
ISIN: FR0011191766 – Ticker: EOSI

Next press release: Next press release: revenue for the 1st half of 2015, on July 20, 2015 (after market).

**About EOS imaging:**

EOS imaging designs, develops, and markets EOS®, an innovative medical imaging system based on technology that enabled Georges Charpak to win the Nobel Prize for Physics, as well as associated solutions. The Company is authorized to market in 48 countries, including the United States (FDA), Japan and the European Union (EU). As of December 31, 2014 the Group posted 2014 consolidated revenue of €20.1 million and employed 107 people including an R&D team of 39 engineers. The Group is based in Paris and holds five subsidiaries in Besançon (France), Cambridge (Massachusetts), Montreal (Canada) and Frankfurt (Germany), and Singapore.

**Contacts:**

**Anne Renevot**

CFO

Ph: +33 (0)1 55 25 61 24

[investors@eos-imaging.com](mailto:investors@eos-imaging.com)

**NewCap**

Financial communication and investor relations

Antoine Denry/ Pierre Laurent

Ph: +33 (0)1 44 71 94 91

[eosimaging@newcap.fr](mailto:eosimaging@newcap.fr)

**The Ruth Group (US)**

Press relations / Melanie Sollid-Penton

Ph: 646-536-7023

[msollid@theruthgroup.com](mailto:msollid@theruthgroup.com)